Takeda Pharmaceutical Co Ltd (TAK) revenue by segment
TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$21.41+0.14 (+0.66%)
Close on Nov 19, 2026Market cap $73.79BP/E –Yield –
Doanh thu theo bộ phận của Takeda Pharmaceutical Co Ltd
Periods
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales of pharmaceutical products | ¥4.42T | ¥4.50T | ¥4.16T | ¥3.92T | ¥3.30T | ¥3.11T | ¥3.20T | ¥2.03T | ¥1.69T | ¥1.67T | 98.2% | -1.6% |
| Total Gastroenterology | ¥1.41T | ¥1.36T | ¥1.22T | ¥1.09T | ¥875.69B | ¥777.80B | ¥697.90B | ¥539.32B | ¥452.03B | – | 31.2% | +3.7% |
| Total PDT | ¥1.06T | ¥1.03T | ¥903.70B | ¥765.36B | – | – | – | – | – | – | 23.5% | +2.4% |
| ENTYVIO | ¥958.04B | ¥914.10B | ¥800.92B | ¥702.74B | ¥521.78B | ¥429.28B | ¥347.20B | ¥269.20B | ¥201.35B | – | 21.3% | +4.8% |
| Immunoglobulin | ¥790.57B | ¥757.77B | ¥644.59B | ¥522.21B | ¥385.86B | ¥334.87B | ¥298.70B | ¥73.46B | ¥12.25B | – | 17.5% | +4.3% |
| Total Rare Diseases | ¥762.70B | ¥752.82B | ¥688.42B | ¥639.77B | ¥611.20B | ¥591.75B | ¥634.89B | ¥129.42B | ¥0 | – | 16.9% | +1.3% |
| Total Oncology | ¥580.13B | ¥560.43B | ¥462.36B | ¥438.74B | ¥468.73B | ¥416.51B | ¥420.96B | ¥399.44B | ¥377.42B | – | 12.9% | +3.5% |
| Total Neuroscience | ¥414.34B | ¥565.82B | ¥627.01B | ¥637.71B | ¥482.29B | ¥417.30B | ¥438.52B | ¥154.67B | ¥82.11B | – | 9.2% | -26.8% |
| Total Other | ¥223.96B | ¥257.39B | ¥315.70B | ¥372.69B | ¥624.15B | ¥574.07B | ¥704.76B | ¥780.90B | ¥842.55B | – | 5.0% | -13.0% |
| TAKHZYRO | ¥223.92B | ¥223.16B | ¥178.68B | ¥151.80B | ¥103.24B | ¥86.72B | ¥68.27B | ¥9.73B | ¥0 | – | 5.0% | +0.3% |
| VYVANSE/ELVANSE | ¥203.23B | ¥350.61B | ¥423.22B | ¥459.29B | ¥327.05B | ¥271.53B | ¥274.08B | ¥49.35B | ¥0 | – | 4.5% | -42.0% |
| GATTEX/REVESTIVE | ¥145.66B | ¥146.29B | ¥119.25B | ¥93.08B | ¥75.75B | ¥64.56B | ¥61.81B | ¥12.75B | ¥0 | – | 3.2% | -0.4% |
| TAKECAB/VOCINTI | ¥143.68B | ¥130.76B | ¥118.53B | ¥108.72B | ¥102.40B | ¥84.82B | – | – | – | – | 3.2% | +9.9% |
| Albumin | ¥140.32B | ¥141.38B | ¥133.99B | ¥121.45B | ¥90.04B | ¥57.58B | ¥67.22B | ¥12.30B | ¥2.39B | – | 3.1% | -0.8% |
| ADCETRIS | ¥140.21B | ¥129.03B | ¥109.43B | ¥83.94B | ¥69.19B | ¥59.43B | ¥52.67B | ¥42.90B | ¥38.51B | – | 3.1% | +8.7% |
| TRINTELLIX | ¥121.84B | ¥125.74B | ¥104.80B | ¥100.08B | ¥82.32B | ¥68.87B | ¥70.67B | ¥57.55B | ¥48.37B | – | 2.7% | -3.1% |
| LEUPLIN/ENANTONE | ¥120.79B | ¥119.27B | ¥107.35B | ¥111.31B | ¥106.46B | ¥95.37B | ¥109.05B | ¥110.07B | ¥108.06B | – | 2.7% | +1.3% |
| Others | ¥106.78B | ¥61.04B | ¥57.24B | ¥75.11B | ¥82.88B | ¥99.66B | ¥103.54B | ¥68.25B | ¥70.62B | – | 2.4% | +74.9% |
| ADVATE | ¥105.52B | ¥111.76B | ¥122.91B | ¥118.19B | ¥118.49B | ¥128.54B | ¥157.86B | ¥32.10B | ¥0 | – | 2.3% | -5.6% |
| ELAPRASE | ¥100.49B | ¥97.24B | ¥91.56B | ¥85.32B | ¥73.12B | ¥68.79B | ¥67.92B | ¥15.08B | ¥0 | – | 2.2% | +3.3% |
| Out-licensing and service income | ¥82.61B | ¥85.58B | ¥100.11B | ¥105.20B | ¥273.28B | ¥92.44B | ¥87.04B | ¥70.95B | ¥76.69B | ¥60.14B | 1.8% | -3.5% |
| NINLARO | ¥82.11B | ¥91.24B | ¥87.36B | ¥92.69B | ¥91.20B | ¥87.40B | ¥77.56B | ¥62.17B | ¥46.43B | – | 1.8% | -10.0% |
| REPLAGAL | ¥80.43B | ¥77.85B | ¥73.55B | ¥66.74B | ¥51.71B | ¥51.76B | ¥51.25B | ¥11.44B | ¥0 | – | 1.8% | +3.3% |
| ICLUSIG | ¥75.05B | ¥70.73B | ¥54.71B | ¥47.21B | ¥34.86B | ¥34.19B | ¥31.82B | ¥28.71B | ¥23.12B | – | 1.7% | +6.1% |
| Total Vaccines | ¥59.61B | ¥55.41B | ¥50.36B | ¥78.66B | – | – | – | – | – | – | 1.3% | +7.6% |
| ADYNOVATE/ADYNOVI | ¥56.69B | ¥64.61B | ¥66.31B | ¥66.55B | ¥60.73B | ¥58.07B | ¥58.67B | ¥10.74B | ¥0 | – | 1.3% | -12.3% |
| FRUZAQLA | ¥55.11B | ¥47.95B | ¥10.08B | ¥0 | ¥0 | – | – | – | – | – | 1.2% | +14.9% |
| LIVTENCITY | ¥46.91B | ¥33.00B | ¥19.09B | ¥10.50B | ¥1.33B | ¥0 | – | – | – | – | 1.0% | +42.2% |
| QDENGA | ¥40.77B | ¥35.58B | ¥9.56B | ¥144.00M | – | – | – | – | – | – | 0.9% | +14.6% |
| DEXILANT | ¥37.26B | ¥38.55B | ¥45.28B | ¥69.37B | ¥50.76B | ¥55.57B | ¥62.80B | ¥69.20B | ¥65.74B | – | 0.8% | -3.3% |
| ALUNBRIG | ¥36.93B | ¥36.43B | ¥28.52B | ¥20.56B | ¥13.64B | ¥8.81B | ¥7.24B | ¥5.20B | ¥2.83B | – | 0.8% | +1.4% |
| FEIBA | ¥32.87B | ¥39.43B | ¥40.54B | ¥41.27B | ¥39.16B | ¥44.50B | ¥51.51B | ¥9.63B | ¥0 | – | 0.7% | -16.6% |
| HEMOFIL/IMMUNATE/IMMUNINE | ¥25.38B | ¥25.59B | ¥19.52B | ¥19.58B | ¥17.72B | ¥18.66B | – | – | – | – | 0.6% | -0.8% |
| VONVENDI | ¥25.28B | ¥20.93B | ¥16.19B | ¥12.22B | ¥8.77B | – | – | – | – | – | 0.6% | +20.8% |
| ADDERALL XR | ¥24.75B | ¥28.43B | ¥41.76B | ¥28.59B | ¥20.89B | – | ¥24.31B | ¥5.40B | ¥0 | – | 0.5% | -13.0% |
| ADZYNMA | ¥11.96B | ¥7.08B | ¥425.00M | ¥0 | – | – | – | – | – | – | 0.3% | +68.8% |
| FOSRENOL | ¥8.84B | ¥7.91B | ¥13.53B | ¥13.53B | ¥13.61B | – | – | – | – | – | 0.2% | +11.8% |
| EOHILIA | ¥8.78B | ¥5.45B | ¥200.00M | ¥0 | – | – | – | – | – | – | 0.2% | +61.0% |
| RESOLOR/MOTEGRITY | ¥7.26B | ¥19.48B | ¥20.88B | – | – | – | – | – | – | – | 0.2% | -62.7% |
| AZILVA | ¥7.14B | ¥11.81B | ¥33.64B | ¥72.90B | – | – | – | – | – | – | 0.2% | -39.5% |
| VPRIV | – | ¥53.46B | ¥51.30B | ¥48.37B | ¥42.41B | ¥38.52B | ¥38.01B | ¥8.69B | ¥0 | – | – | – |
| PANTOLOC/CONTROLOC | – | ¥44.59B | ¥46.50B | ¥45.52B | ¥40.28B | ¥43.12B | ¥49.46B | ¥61.63B | ¥65.83B | – | – | – |
| ALOFISEL | – | – | ¥3.51B | ¥2.73B | ¥1.84B | ¥784.00M | ¥373.00M | ¥45.00M | ¥0 | – | – | – |
| AZILVA-F | – | – | ¥33.64B | ¥72.90B | ¥76.30B | ¥82.21B | ¥76.75B | ¥70.76B | ¥63.97B | – | – | – |
| Total PDT Immunology | – | – | ¥818.57B | ¥678.44B | ¥506.95B | ¥420.39B | ¥394.17B | ¥93.48B | ¥16.43B | – | – | – |
| Total Rare Hematology | – | – | ¥305.30B | ¥304.72B | ¥283.69B | ¥289.80B | ¥334.24B | ¥66.70B | ¥0 | – | – | – |
| VELCADE | – | – | ¥5.54B | ¥27.76B | ¥110.05B | ¥101.11B | ¥118.32B | ¥127.87B | ¥137.31B | – | – | – |
| RECOMBINATE | – | – | ¥12.05B | ¥12.76B | ¥12.30B | ¥13.39B | ¥17.09B | ¥2.77B | – | – | – | – |
| EXKIVITY | – | – | ¥3.46B | ¥3.73B | ¥962.00M | ¥0 | – | – | – | – | – | – |
| Total Rare Genetics and Other | – | – | ¥465.40B | ¥418.72B | ¥327.51B | ¥301.95B | – | – | – | – | – | – |
| Intuniv | – | – | ¥33.56B | ¥16.35B | ¥18.94B | – | – | – | – | – | – | – |
| LOTRIGA | – | – | – | ¥16.73B | ¥32.69B | ¥31.77B | ¥31.75B | ¥30.86B | ¥28.49B | – | – | – |
| FIRAZYR | – | – | – | – | ¥26.69B | ¥26.82B | ¥32.66B | ¥6.42B | ¥0 | – | – | – |
| Total Hereditary Angioedema | – | – | – | – | ¥153.59B | ¥139.33B | ¥129.82B | ¥20.42B | ¥0 | – | – | – |
| Total Rare Metabolic | – | – | – | – | ¥172.60B | ¥162.62B | ¥170.83B | ¥42.30B | ¥0 | – | – | – |
| TAKECAB-F | – | – | – | – | ¥102.40B | ¥84.82B | ¥72.71B | ¥58.24B | ¥48.49B | – | – | – |
| NATPARA/NATPAR | – | – | – | – | ¥5.35B | ¥3.55B | ¥13.64B | ¥7.09B | ¥0 | – | – | – |
| Diabetes | – | – | – | – | ¥133.04B | – | – | – | – | – | – | – |
| NESINA/VIPIDIA-F | – | – | – | – | – | ¥57.67B | ¥57.96B | ¥54.79B | ¥50.23B | – | – | – |
| Cinryze | – | – | – | – | – | – | ¥24.35B | ¥3.10B | ¥0 | – | – | – |
| Kalbitor | – | – | – | – | – | – | ¥4.54B | ¥1.17B | ¥0 | – | – | – |
Theo khu vực
| Doanh thu | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | ¥2.16T | ¥2.38T | ¥2.20T | ¥2.10T | ¥1.71T | ¥1.57T | ¥1.60T | ¥828.99B | ¥598.34B | ¥520.16B | 48.0% | -9.0% |
| Europe and Canada | ¥1.15T | ¥1.06T | ¥966.84B | ¥842.67B | ¥739.17B | ¥666.18B | ¥645.53B | ¥405.64B | ¥313.72B | ¥279.69B | 25.4% | +8.6% |
| Japan | ¥433.11B | ¥418.46B | ¥451.39B | ¥512.04B | ¥658.98B | ¥559.75B | ¥592.79B | ¥571.02B | ¥580.35B | ¥655.34B | 9.6% | +3.5% |
| Latin America | ¥254.13B | ¥235.85B | ¥198.10B | ¥160.38B | ¥128.47B | ¥121.64B | ¥143.46B | ¥88.12B | ¥75.66B | ¥72.52B | 5.6% | +7.8% |
| China | ¥195.14B | ¥191.74B | ¥174.84B | ¥150.97B | – | – | – | – | – | – | 4.3% | +1.8% |
| Other | ¥133.89B | ¥128.85B | ¥117.91B | ¥95.18B | ¥68.95B | ¥68.52B | ¥71.26B | ¥38.32B | ¥30.19B | ¥33.99B | 3.0% | +3.9% |
| Asia (excluding Japan & China) | ¥98.67B | ¥99.39B | ¥86.38B | ¥74.03B | – | – | – | – | – | – | 2.2% | -0.7% |
| Russia/CIS | ¥79.72B | ¥72.36B | ¥72.59B | ¥88.43B | ¥62.06B | ¥57.56B | ¥76.84B | ¥59.74B | ¥68.24B | ¥57.55B | 1.8% | +10.2% |
| Asia (excluding Japan) | – | – | ¥261.22B | ¥225.01B | ¥196.96B | ¥156.24B | ¥165.40B | – | – | – | – | – |
| Asia | – | – | – | – | – | ¥156.24B | ¥165.40B | ¥105.41B | ¥104.03B | ¥112.80B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Takeda Pharmaceutical (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Takeda Pharmaceutical, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?